Morgan Stanley Biond Vax Pharmaceuticals Ltd. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.96 - $1.26 $10,263 - $13,470	-10,691 Reduced 32.12%	22,590 $17,000
Q2 2022 Oct 27, 2022	SELL	$1.16 - $1.88 $16,647 - $26,979	-14,351 Reduced 30.13%	33,281 $39,000
Q2 2022 Aug 15, 2022	SELL	$1.16 - $1.88 $16,647 - $26,979	-14,351 Reduced 30.13%	33,281 $39,000
Q1 2022 Oct 27, 2022	BUY	$1.15 - $2.34 $16,503 - $33,581	14,351 Added 43.12%	47,632 $79,000
Q1 2022 May 13, 2022	BUY	$1.15 - $2.34 $4,610 - $9,381	4,009 Added 9.19%	47,632 $79,000
Q4 2021 Feb 14, 2022	SELL	$1.48 - $2.92 $2,843 - $5,609	-1,921 Reduced 4.22%	43,623 $103,000
Q3 2021 Nov 15, 2021	BUY	$2.15 - $3.44 $97,919 - $156,671	45,544 New	45,544 $100,000

Ticker BVXV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,678,800
Market Cap $12M
Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Götting...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.